Get Updates

Advocacy

FORCE advocates for families facing hereditary breast and ovarian cancer in areas such as access to care, research funding, insurance, and privacy.

Advocacy > Issues > Population-Wide BRCA Testing

| More

Newsflash

11/8/17
FORCE, along with 60 other patient groups, is asking the Senate to preserve medical expense deductions in any forthcoming tax reform legislation.  

10/25/17
We joined over 100 Defense Health Research Consortium orgs in supporting DoD research funding. Learn more...

9/22/17
Check out this new video w/FORCE & 15 other cancer orgs representing patients, physicians, nurses, & social workers. Oppose Graham-Cassidy! See Video...

9/14/17
FORCE reps were in St. Louis today for an ICER hearing on the value and cost of PARP inhibitors for ovarian cancer patients.

Population-Wide BRCA Testing

Genetic Testing & Counseling

Overview

In 2014, Dr. Mary-Claire King, whose research led to the discovery of the BRCA1 gene associated with hereditary breast cancer and ovarian cancer, proposed that genetic testing for the BRCA1 and BRCA2 gene mutations become routine for all U.S. women over age 30. Among other things, King cited an Israeli study which revealed that Ashkenazi Jewish women with no family history of cancer—but who tested positive for a BRCA genetic mutation—have high rates of breast and ovarian cancer. 

Demonstration studies in the Ashkenazi Jewish population have shown that screening for the three BRCA founder mutations may be cost-effective and identifies carriers who would not have been suspected on the basis of their family cancer history. However, applying this to the broader, more diverse U.S. population may not yield the same results.

FORCE continues to consult with its scientific advisory board and other experts to evaluate these proposed changes and their implications on health care practice.

Search Policy Issues by Keyword

FORCE:Facing Our Risk of Cancer Empowered